Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06775431

Comparing Prophylactic Intravenous Pethidine and Intrathecal Pethidine in Preventing Post Spinal Shivering in Caesarean Section

The goal of this clinical trial is to assess the effect of IV pethidine and intrathecal pethidine on the incidence, onset, duration, and intensity of shivering in females undergoing caesarean section. The main question it aims to answer is: which route is more efficacious in preventing shivering.

Researchers will compare IV pethidine and intrathecal pethidine to see their effects on post spinal shivering, their effects on hemodynamic stability, nausea, vomiting, and sedation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

El-Shatby University Hospital

Alexandria, Alexandria Governorate, Egypt

Location status: Recruiting

Location contact

Mai A El-Sayed, Lecturer of Anesthesia

CONTACT

Moutaz A Ghandour, Lecturer of Anesthesia

CONTACT

Shahira El Metainy, Professor of Anesthesia

CONTACT

[email protected]

00201227498438

Shahira El Metainy, Professor of Anesthesia

CONTACT

About this study

This study will be a single blinded, randomized, prospective controlled study. After obtaining written informed consents, 86 patients of American Society of Anesthesiologists physical status II, aged 20-40 years old, undergoing spinal anesthesia for elective cesarean section will be investigated at El-Shatby University Hospital.

The patients will be randomized into two groups of n=43 each using a computer-generated sequence. Allocation concealment will be done using sealed envelope technique. Depending on the group allocation either to receive IV Pethidine 0.5mg/kg (Group A n=43 patients) as premedication mixed into 10 ml isotonic saline slowly IV or intrathecal Pethidine 0.2 mg/kg and 2.5 ml Bupivacaine 0.5% (Group B n=43 patients). SA will be given at either L3-L4 or L4-L5 in the sitting position by the anesthetist using 22-25-gauge Quincke spinal needles. Patients will be covered with drapes but not actively warmed. 10mg ephedrine will be given if the patient becomes hypotensive (hypotension is defined as a decrease in MAP of >20% from the baseline). 0.5 mg atropine IV will be given if HR less than 50 beats/min. Rescue 4 mg ondansetron IV will be given for vomiting episodes. Room temperature will be maintained about 21 - 24ºC during the perioperative period in the OR and in the PACU, using temperature control system. The presence of shivering will be observed and graded after spinal injection by using Tsai and Chu Scale.

The following parameters will be measured:

  • Vital signs (heart rate, and blood pressure) will be measured at baseline and every 5 minutes after administration of the drug for 30 minutes, then every 15 minutes till the end of surgery and every 30 minutes in the first two hours postoperatively
  • Body temperature (in degrees Celsius), will be measured, using axillary thermometer before drug administration then every 15 minutes till the end of surgery. After surgery, axillary temperature will be measured every 30 minutes for 2 hours.
  • Using Tsai and Chu Scale for shivering assessment, the incidence, duration, time interval from onset of spinal block to shivering occurrence, and intensity of shivering will be recorded every 15 minutes during the surgery and every 30 minutes for 2 hours postoperatively in the recovery room.
  • Complications of the drugs, such as nausea, vomiting and sedation will be recorded.

The primary aim of this study will be to assess the effect of IV pethidine and intrathecal pethidine on the incidence, onset, duration, and intensity of shivering. The secondary aims will be to assess the effect of different routes of administration of the drug on hemodynamic stability, nausea, vomiting, and sedation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-

Exclusion criteria

  • contraindications to spinal
  • uncontrolled hypertension, diabetes mellitus, hepatic, pulmonary diseases, and thyroid disease
  • obesity (BMI >35)
  • drug allergy
  • temperature below 36 degrees celcius or above 37.5 degrees celcius

Treatment and study plan

Pethidine Hydrochloride 50 Mg/mL Solution for Injection

Drug

Pethidine will be administered intravenously in group A 0.5 mg/kg as premedication

Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally

Drug

0.2 mg/kg pethidine in trathecally will be administered with bupivacaine 0.5% in group B

Primary outcomes

  1. Shivering incidence

    Time frame: every 15 minutes during the surgery and every 30 minutes for 2 hours postoperatively

    The primary aim of this study will be to assess the effect of IV pethidine and intrathecal pethidine on the incidence of shivering

  2. Onset of shivering

    Time frame: every 15 minutes during the surgery and every 30 minutes for 2 hours postoperatively

    The primary aim of this study will be to assess the effect of IV pethidine and intrathecal pethidine on the onset of shivering

  3. Duration of shivering

    Time frame: every 15 minutes during the surgery and every 30 minutes for 2 hours postoperatively

    The primary aim of this study will be to assess the effect of IV pethidine and intrathecal pethidine on the duration of shivering

  4. Shivering intensity

    Time frame: every 15 minutes during the surgery and every 30 minutes for 2 hours postoperatively

    The primary aim of this study will be to assess the effect of IV pethidine and intrathecal pethidine on the intensity of shivering, using the Tsai and Chu Scale

    The intensity of shivering using Tsai and Chu scale is measured as follows:

    0: no shivering

    • piloerection or peripheral vasoconstriction, but no visible shivering
    • muscular activity in only one muscle group
    • muscular activity in more than one muscle group, but not generalized
    • shivering involving the whole body

Secondary outcomes

  1. Hemodynamic stability

    Time frame: at baseline and every 5 minutes after administration of the drug for 30 minutes, then every 15 minutes till the end of surgery and every 30 minutes in the first 2 hours postoperatively

    The secondary outcome is to assess the effect of different routes of administration of the drug on hemodynamic stability, by measuring the heart rate and blood pressure

  2. Incidence of vomiting

    Time frame: from administration of spinal till 2 hours postoperatively

    The secondary outcome is to assess the effect of different routes of administration of the drug on incidence of vomiting

  3. Incidence of sedation

    Time frame: from administration of spinal till 2 hours postoperatively

    The secondary outcome is to assess the effect of different routes of administration of the drug on incidence of sedation

Other outcomes

  1. Body Temperature

    Time frame: before administration of the drug, then every 15 minutes till the end of surgery and every 30 minutes for 2 hours postoperatively

    Body temperature will be measured using an axillary thermometer

Study contacts

Contact information is provided by the study sponsor or research team.

Mai A El-Sayed, Lecturer of Anesthesia

CONTACT

[email protected]

00201287459922

Sponsors and collaborators

Lead sponsor

Alexandria University

Other

Registry information

Official study title

Comparison of Prophylactic Intravenous Pethidine Versus Intrathecal Pethidine in Preventing Post Spinal Shivering in Caesarean Section

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 15, 2025
Registry last updated
Jan 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.